Stocks Showing Improved Relative Strength: Lannett – Investor's Business Daily

This post was originally published on this site

Lannett (LCI) saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 68 to 71.

X IBD’s proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock’s price action over the last 52 weeks compares to the rest of the market.

Over 100 years of market history shows that the best stocks typically have an RS Rating of over 80 as they launch their largest climbs. See if Lannett can continue to show renewed price strength and clear that threshold.


See How IBD Helps You Make More Money In Stocks


Lannett is now considered extended and out of buy range after clearing a 23.85 buy point in a first-stage double bottom. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

Although earnings and sales growth came in at -22% and -4%, respectively, in the latest report, that marked acceleration for both the top and bottom lines. Lannett is expected to release its next quarterly numbers on or around Feb. 1.

The company earns the No. 5 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals (ANIP) is the top-ranked stock within the group.

RELATED:

Which Stocks Are Showing Improved Technical Action?

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

This post was originally published on *this site*